Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: Final results of a pilot phase II study

Haematologica

Volumn 101, Issue 4, 2016, Pages e139-e141

  Federico, Massimo ^a   Luminari, Stefano ^a   Pellegrini, Cinzia ^b   Merli, Francesco ^c   Pesce, Emanuela Anna ^a   Chauvie, Stephane ^d   Gandolfi, Letizia ^b   Capodanno, Isabella ^c   Salati, Massimiliano ^a   Argnani, Lisa ^b   Zinzani, Pier Luigi ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

ABVD; Brentuximab vedotin; Early; Hodgkin lymphoma; Intermediate; Radiotherapy; Toxicity

Indexed keywords

ALBUMIN; BLEOMYCIN; BRENTUXIMAB VEDOTIN; DACARBAZINE; DOXORUBICIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; VINBLASTINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CYSTITIS; DIARRHEA; EDEMA; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FEVER; HEADACHE; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERURICEMIA; LETTER; LEUKOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PRURITUS; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; CLINICAL TRIAL; DRUG ADMINISTRATION; GAMMA RADIATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PILOT STUDY; REMISSION; THERAPEUTIC USE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; GAMMA RAYS; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEUTROPENIA; PILOT PROJECTS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84962343919     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.138388     Document Type: Letter

References (13)

1. Canellos GP, Rosenberg SA, Friedberg JW, et al. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014; 32(3): 163-168.
2. Howlader N, Noone AM, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: US National Cancer Institute, 2014.
3. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEA COPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009; 27(5): 805-811.
4. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Longterm cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003; 21(18): 3431-3439.
5. Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2011; 2011: 323-329.
6. van Eggermond AM, Schaapveld M, Lugtenburg PJ, et al. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. Blood. 2014; 124(3): 319-327.
7. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30(18): 2183-2189.
8. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015; 125(8): 1236-1243.
9. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013; 14(13): 1348-1356.
10. Meignan M, Barrington S, Itti E, et al. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma. 2014; 55(1): 31-37.
11. Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014; 32(12): 1188-1194.
12. Pro B, Advani R, Brice P, et al. Four-year survival data from an ongoing pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2014; 124(21).
13. Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015; 126(26): 2798-804.